LLY

Eli Lilly & Co
D

LLY

Arincen80/100B
1,438.17
USD
6.03
(0.42%)
Post Trading·1,447.85USD+9.68(+0.67%)
Last updated: · Delayed 15 min
Fair value1,289.63Plus+12%1,022Price 1,438.171,672
Q4 FY2026 · Earnings report
EPS estimate 11.19Revenue estimate 24.58B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Eli Lilly & Co revenue 1985–2026

Eli Lilly & Co's revenue in Q3 FY2026, the three months to 30 September 2026, was 24.40B USD, up 38.6% on the same quarter a year before. Eli Lilly & Co's revenue over the last twelve months was 86.46B USD, up 45.5% on the twelve months before. In fiscal year 2025 it was 65.18B USD, up 44.7% on the year before.

Last updated 10 Nov 2026 · Next report 3 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202686.46B+45.51%72.31B27.58B
FY202531 Dec 202565.18B+44.70%54.13B20.64B
FY202431 Dec 202445.04B+32.00%36.63B10.59B
FY202331 Dec 202334.12B+19.56%27.04B5.24B
FY202231 Dec 202228.54B+0.79%21.91B6.24B
FY202131 Dec 202128.32B+15.40%21.01B5.58B
FY202031 Dec 202024.54B+9.95%19.06B6.19B
FY201931 Dec 201922.32B+3.84%17.60B8.32B
FY201831 Dec 201821.49B+7.61%16.81B3.23B
FY201731 Dec 201719.97B-5.88%15.53B-204.10M
FY201631 Dec 201621.22B+6.33%15.51B2.74B
FY201531 Dec 201519.96B+1.75%14.92B2.41B
FY201431 Dec 201419.62B-15.13%14.68B2.39B
FY201331 Dec 201323.11B+2.25%18.21B4.68B
FY201231 Dec 201222.60B-6.93%17.81B4.09B
FY201131 Dec 201124.29B+5.25%19.22B4.35B
FY201031 Dec 201023.08B+5.68%18.71B5.07B
FY200931 Dec 200921.84B+7.19%17.59B4.33B
FY200831 Dec 200820.37B+9.33%16.00B-2.07B
FY200731 Dec 200718.63B+18.75%14.38B2.95B
FY200631 Dec 200615.69B+7.14%12.14B2.66B
FY200531 Dec 200514.65B+5.68%11.17B1.98B
FY200431 Dec 200413.86B+10.14%10.63B1.81B
FY200331 Dec 200312.58B+13.59%9.91B2.56B
FY200231 Dec 200211.08B-4.03%8.90B2.71B
FY200131 Dec 200111.54B+6.26%9.38B2.78B
FY200031 Dec 200010.86B+8.59%9.24B3.06B
FY199931 Dec 199910.00B+8.29%8.34B2.72B
FY199831 Dec 19989.24B+15.64%7.71B2.10B
FY199731 Dec 19977.99B+14.14%6.55B-385.10M
FY199631 Dec 19967.00B+3.47%5.67B1.52B
FY199531 Dec 19956.76B+18.42%5.43B2.29B
FY199431 Dec 19945.71B-11.48%4.46B1.29B
FY199331 Dec 19936.45B+4.62%4.89B480.20M
FY199231 Dec 19926.17B+7.71%4.64B708.70M
FY199131 Dec 19915.73B+10.29%4.37B1.31B
FY199031 Dec 19905.19B+24.33%3.92B1.13B
FY198931 Dec 19894.18B+2.60%3.15B939.50M
FY198831 Dec 19884.07B+11.69%2.94B761.00M
FY198731 Dec 19873.64B-2.06%2.53B643.70M
FY198631 Dec 19863.72B+13.75%2.55B558.20M
FY198531 Dec 19853.27B—2.23B517.60M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Eli Lilly & Co revenue growth by segment

Q3 FY2026 against Q3 FY2025

Cardiometabolic Health19.76B
+50.0%
Oncology2.60B
+8.0%
Immunology1.44B
+5.3%
Neuroscience444.00M
+40.6%

Eli Lilly & Co revenue by segment over time

Product Collaboration and Other Revenue Animal Health Products Human Pharmaceutical Products
Fiscal yearProductCollaboration and Other RevenueAnimal Health ProductsHuman Pharmaceutical Products
FY202560.96B +49.6%4.22B -1.7%— —
FY202440.75B +41.4%4.29B -19.1%— —
FY202328.81B +13.2%5.31B +72.5%— —
FY202225.46B -1.9%3.08B +30.4%— —
FY202125.96B +14.4%2.36B +27.9%— —
FY202022.69B +11.4%1.85B -5.0%— —
FY201920.38B 1.94B — —
FY2018— — 1.62B -47.5%12.35B -37.6%
FY2017— — 3.09B -2.3%19.79B +9.5%
FY2016— — 3.16B -0.7%18.06B

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Eli Lilly & Co's revenue

Source: Financial Modeling Prep